finance.yahoo.com Earnings
Faron Pharmaceuticals, Central Asia Metals, Gelion, S&U, Mila Resources, Georgina Energy
Faron Pharmaceuticals Limited (AIM:FARN) is set to start its phase IIb BEXERA trial for blood cancer drug bexmarilimab in the second half of this year. It'll test the drug in 90 patients across the US, Europe and the UK, funded by a โฌ40 million rights issue. Central Asia Metals PLC (AIM:CAML, OTC:CAMLF) has nearly doubled first-half earnings on โฆ